Veritas Aortic Solutions Secures $12M in Seed Funding for Integrated Transcatheter Aortic System TVARC

Jun 12, 2026 21:10 CST Updated 21:10

Veritas Aortic Solutions

Developer of Novel Transcatheter Therapies

In June 2026, medical device company Veritas Aortic Solutions announced the completion of a $12 million angel financing round. Cedars-Sinai and several other investors participated in this round of investment. The funds will primarily be used to support its core product—Transcatheter Integrated Aortic Valve System (TVARC)continuous development until the first-in-human clinical trial is conducted。

This integrated solution includes:Transcatheter Aortic Valve + Transcatheter Aortic Root System + Endovascular Stent Graft. This is an integrated, fully endovascular solution in the aortic field that has been challenged multiple times but never successfully conquered.

Total Endovascular Aortic Repair: The Challenge Lies in the Integrated DesignTreatment

Type A aortic dissection typically involves the aortic valve root and ascending aorta,YesCardiovascular emergencies with high clinical case fatality rates. In current clinical practice, endovascular minimally invasive treatment for these conditions faces unique anatomical and physiological constraints:

Vascular Intervention Protocol:For Stanford type B aortic dissection, or for distal endovascular intervention following the management of type A dissection, thoracic endovascular aortic repair (TEVAR) can be performed; the use of endovascular stents enables luminal reconstruction of the dissection or aneurysm.。
Transcatheter Aortic Valve Replacement:Transcatheter aortic valve replacement has gradually expanded from high-risk patients to the general population. However, aortic valve replacement in patients with concomitant Type A aortic dissection remains a "no-man's land" at the interface of disciplines. Currently, management of such patients still relies on cardiac surgical intervention.
Coronary ostium dissection is common.: The key to performing endovascular reconstruction of the ascending aortic lumen combined with valve replacement in patients with aortic dissection lies in managing the dissection and intimal peeling at the coronary ostia. Meanwhile, it is essential to ensure normal blood flow perfusion at the coronary ostia and maintain the opening and closing function of the aortic valve, which renders pure endovascular approaches unsuitable for the complex anatomy of this region.

TVARC: Integrated Aortic Intervention Solution

The TVARC system is designed to provide a minimally invasive interventional option for high-risk patients with aortic root and ascending aorta lesions who cannot tolerate traditional open-chest surgery. Its system design integrates multiple technical features of structural heart disease and large vessel intervention:

1. "Three-in-One" Integrated Structure

TVARC is an implant that integrates multiple functional components into a single physical entity and is deployed via a fully interventional procedure. It includes:

Biological Aortic Valve: TAVR technology is relatively mature,Used to replace damaged or diseased aortic valves, restoring normal unidirectional hemodynamic function.
Ascending Aortic Prosthetic Graft: Used to isolate and seal the diseased or dissected aortic wall, reconstructing the main channel of the aorta. After the stent graft is deployed, it can simultaneously restore blood supply to the brain and upper extremities in a single procedure, avoiding the risk of inadequate sealing associated with the assembly of multiple modular stent components. HoweverReconstruction of the ascending aorta relies primarily on open surgical repair, as endovascular procedures currently have stringent patient selection criteria.
Chameleon Eye™ Coronary Artery Perfusion Port: Managing the coronary arteries represents the greatest challenge in total endovascular treatment, typically requiring surgical reimplantation of the left and right coronary ostia onto the graft vessel—a step that is difficult to achieve via a purely endovascular approach. This system features a proprietary design that maintains anatomical alignment with the ostia of the left and right coronary arteries while excluding the aortic wall with the graft vessel, thereby providing an integrated solution for coronary perfusion and ensuring unimpeded blood flow to the myocardium.

2. Transfemoral Delivery System

The system is equipped with a customized transfemoral catheter delivery system. The operator accesses it via puncture of the femoral artery in the thigh, under X-ray and ultrasound guidanceDelivering integrated implants below.

TVARC TechnologyThis represents a major breakthrough in the field of total endovascular treatment for aortic dissection, transforming what was once an extremely high-risk open-chest surgery into a minimally invasive procedure. It holds disruptive significance and can be regarded as the practical realization of the interventional cardiologists’ “idealism” toward total endovascular therapy.

Nirdesh Gupta, Managing Partner of Intellectual Property at Cedars-Sinai

“TVARC represents the kind of patient-centered innovation that we support at Cedars-Sinai, and we are pleased to participate in this round of financing to advance a novel endovascular therapy for diseases of the aortic root and ascending aorta—an area where treatment options have remained largely unchanged for years despite significant patient risk. We believe this technology holds promise to meaningfully improve outcomes for patients facing life-threatening cardiovascular disease.”

J. Brent Ratz, Veritas Aortic Solutions (Co-Founder and CEO)

“After establishing the Veritas project within inQB8 Medical Technologies and rapidly advancing it through prototyping, bench testing, and successful chronic animal studies, we are honored to have secured the support of experienced medtech investors, leading physicians, and world-class medical institutions such as Cedars-Sinai to accelerate our development efforts and bring this technology to clinical application for the first time. Over more than two decades of collaboration, Dr. Quadri and I have jointly developed solutions for multiple cardiovascular conditions. Given the complexity of aortic root and ascending aortic diseases, along with the urgent need for interventional solutions, I believe Veritas will be the most impactful of all our achievements in terms of patient benefit.”

Veritas Aortic Solutions

Veritas Aortic Solutions is an innovative medical device company dedicated to improving outcomes for patients with aortic diseases.

Copyright and Disclaimer: MedTF YiKan aims to build a platform for academic dissemination and media outreach. The copyright of the information contained herein belongs to the respective holders, and we provide it for informational purposes only. If you have any questions or concerns, please contact us.